Skip to main content
Premium Trial:

Request an Annual Quote

Invitae: Robert Dickey, Christine Gorjanc

Invitae named Robert Dickey as interim CFO, effective immediately. Dickey previously worked at Lehman Brothers, conducting mergers and acquisitions and capital markets transactions. In addition to his new position at Invitae, he serves as a member of the board of directors at AngioGenex, SFA Therapeutics, and GSNO Therapeutics. Former interim CFO Christine Gorjanc will return to her prior role as chair of the audit committee and a member of the compensation committee of Invitae's board. Gorjanc and Dickey will both work with the executive leadership team to ensure a smooth transition, while Gorjanc continues to assist the company in searching for a permanent CFO.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.